Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference

The authors aimed to address the challenges associated with immune checkpoint inhibitor-associated acute kidney injury (ICI-AKI), including its epidemiology, diagnosis, management, and implications for immunosuppression and ICI rechallenge. Through a consensus conference, they developed statements highlighting that ICI-AKI affects up to 20% of patients receiving ICIs, with acute tubulointerstitial nephritis being the most common pathology, and emphasized the need for individualized management strategies and further research to improve outcomes.